All In Biotech

Drug Trial Radar · NCT04638660

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

Dec 30, 2020

Primary completion

May 19, 2022

Study completion May 19, 2022

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
First posted
Nov 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are: * To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD) * To evaluate efficacy of Nyxol to improve visual performance * To evaluate the safety of Nyxol

Conditions

  • Dim Light Vision Disturbances

Interventions

  • Phentolamine Ophthalmic Solution 0.75%Drug

    0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

  • Phentolamine Ophthalmic Solution Vehicle (Placebo)Drug

    Topical sterile ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Subjects With 3 Lines mLCVA Improvement in Study EyeTime frame: 8 days

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site 6

    Newport Beach, California

  • Clinical Site 1

    Petaluma, California

  • Clinical Site 3

    Jacksonville, Florida

  • Clinical Site 18

    Jacksonville, Florida

  • Clinical Site 13

    Pittsburg, Kansas

  • Clinical Site 20

    Edgewood, Kentucky

  • Clinical Site 14

    Louisville, Kentucky

  • Clinical Site 10

    Palisades Park, New Jersey

  • Clinical Site 8

    Pennington, New Jersey

  • Clinical Site 4

    Elizabeth City, North Carolina

  • Clinical Site 22

    High Point, North Carolina

  • Clinical Site 9

    High Point, North Carolina

  • Clinical Site 2

    Fargo, North Dakota

  • Clinical Test 15

    Warwick, Rhode Island

  • Clinical Site 11

    Memphis, Tennessee

  • Clinical Site 5

    San Antonio, Texas

  • Clinical Site 19

    Ogden, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.